"Concerned" J&J hopes to stop monthly Tylenol recalls

The most recent recall of Children's Tylenol and related products is "a matter of great concern," writes Johnson & Johnson CEO Bill Weldon on a company blog. In a sustained GMP embarrassment, the late April recall marks the fourth such Tylenol action in as many months. It follows the mid-March move of quality VP Veronica Cruz to McNeil from J&J, and it precedes McNeil's hiring of independent quality experts. That's a lot of QC horsepower rolling into May, the fifth month; hopefully it will forestall a fifth Tylenol recall. Blog | Item

Suggested Articles

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.

Korean CDMO Samsung Biologics is expanding and China API maker WuXi STA opened a 30,000-square-foot oligonucleotide manufacturing facility.